These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9364245)

  • 21. Bone mineral density of the axial skeleton in acromegaly.
    Ho PJ; Fig LM; Barkan AL; Shapiro B
    J Nucl Med; 1992 Sep; 33(9):1608-12. PubMed ID: 1517833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
    Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
    J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative ultrasound of the heel and some parameters of bone turnover in patients with acromegaly.
    Bolanowski M; Jedrzejuk D; Milewicz A; Arkowska A
    Osteoporos Int; 2002; 13(4):303-8. PubMed ID: 12030545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J; Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of octreotide on lipid metabolism in acromegaly.
    Cohen R; Chanson P; Bruckert E; Timsit J; Legrand A; Harris AG; Guillausseau PJ; Warnet A; Lubetzki J
    Horm Metab Res; 1992 Aug; 24(8):397-400. PubMed ID: 1526629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy.
    Freda PU; Reyes CM; Conwell IM; Sundeen RE; Wardlaw SL
    J Clin Endocrinol Metab; 2003 May; 88(5):2037-44. PubMed ID: 12727951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
    Waśko R; Bolko P; Kostrzewski J; Horst-Sikorska W; Liebert W; Sowiński J
    Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.
    Bielesz BO; Hecking M; Plischke M; Cejka D; Kieweg H; Haas M; Marculescu R; Hörl WH; Bieglmayer C; Sunder-Plassmann G
    Clin Biochem; 2014 Sep; 47(13-14):1316-9. PubMed ID: 24956265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth hormone treatment in adults with GH deficiency: effects on new biochemical markers of bone and collagen turnover.
    Sartorio A; Conti A; Monzani M; Morabito F; Faglia G
    J Endocrinol Invest; 1993 Dec; 16(11):893-8. PubMed ID: 8144866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hormonal interactions of parathormone and calcium metabolism].
    Kovács L
    Orv Hetil; 2003 Jan; 144(1):3-12. PubMed ID: 12635347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
    Mattar P; Alves Martins MR; Abucham J
    Neuroendocrinology; 2010; 92(2):120-7. PubMed ID: 20802256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
    Ezzat S; Ren SG; Braunstein GD; Melmed S
    J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-I independent immunomodulatory effect of GH.
    Hansen TK; Thiel S; Dall R; Rosenfalck AM; Trainer P; Flyvbjerg A; Jørgensen JO; Christiansen JS
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5383-8. PubMed ID: 11701711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
    Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
    J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Octreotide abolishes the acute decrease in bone turnover in response to oral glucose.
    Clowes JA; Allen HC; Prentis DM; Eastell R; Blumsohn A
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4867-73. PubMed ID: 14557467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
    Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
    J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.